DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK

INTRODUCTION: The aim of this study was to evaluate the short-term cost-utility of insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U100) for the treatment of type 2 diabetes in the basal–bolus subgroup of the head-to-head cardiovascular (CV) outcome trial, DEVOTE. METHODS:...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes Ther
Autors principals: Pollock, Richard F., Valentine, William J., Marso, Steven P., Gundgaard, Jens, Hallén, Nino, Hansen, Lars L., Tutkunkardas, Deniz, Buse, John B.
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2018
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5984933/
https://ncbi.nlm.nih.gov/pubmed/29713962
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-018-0430-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars